Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance

Journal of Clinical Oncology

Volumn 27, Issue 4, 2009, Pages 542-549

  Van Agthoven, Ton ^a   Sieuwerts, Anieta M ^a   Meijer van Gelder, Marion E ^a   Look, Maxime P ^a   Smid, Marcel ^a   Veldscholte, Jos ^a   Sleijfer, Stefan ^a   Foekens, John A ^a   Dorssers, Lambert C J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; CRK ASSOCIATED SUBSTRATE PROTEIN 3; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 7; MESSENGER RNA; PROTEIN KINASE B BETA; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE MARKER; DISTANT METASTASIS; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC THERAPY; TLE3 GENE; TRERF1 GENE; TUMOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TAMOXIFEN;

EID: 59149094599     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.1462     Document Type: Article

References (68)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Jordan VC: Third annual William L. McGuire memorial lecture: Studies on the estrogen receptor in breast cancer: 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267-285, 1995
3. Jaiyesimi IA, Buzdar AU, Decker DA, et al: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13:513-529, 1995
4. Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2:101-112, 2002
5. Clarke R, Liu MC, Bouker KB, et al: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339, 2003
6. Osborne CK, Shou J, Massarweh S, et al: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-870s, 2005
7. Lewis JS, Jordan VC: Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247-263, 2005
8. Riggins RB, Schrecengost RS, Guerrero MS, et al: Pathways to tamoxifen resistance. Cancer Lett 256:1-24, 2007
9. vant Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
10. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
11. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
12. Wang Y, Klijn JG, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
13. Jansen MP, Foekens JA, van Staveren IL, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740, 2005
14. Foekens JA, Atkins D, Zhang Y, et al: Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 24:1665-1671, 2006
15. Uren AG, Kool J, Berns A, et al: Retroviral insertional mutagenesis: Past, present and future. Oncogene 24:7656-7672, 2005
16. Dorssers LCJ, Van Agthoven T, Dekker A, et al: Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: Identification of bcar-1, a common integration site. Mol Endocrinol 7:870-878, 1993
17. Van Agthoven T, Van Agthoven TLA, Dekker A, et al: Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells. EMBO J 17:2799-2808, 1998
18. Brinkman A, Van der Flier S, Kok EM, et al: BCAR1, a human homologue of the adapter protein p130Cas and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112-120, 2000
19. Van Agthoven T, Veldscholte J, Smid M, et al: Functional screen identifies genes associated with human breast cancer progression. Breast Cancer Res Treat DOI:10.1007/s10549-008-9969-5, 2008
20. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res Treat 100:229-235, 2006
21. Sieuwerts AM, Look MP, Meijer-van Gelder ME, et al: Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12:3319-3328, 2006
22. Jansen MP, Sieuwerts AM, Look MP, et al: HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: A retrospective study. J Clin Oncol 25:662-668, 2007
23. Sieuwerts AM, Usher PA, Meijer-van Gelder ME, et al: Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem 53:1280-1288, 2007
24. Meijer D, Sieuwerts AM, Look MP, et al: Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 15:101-111, 2008
25. Meijer D, Jansen MPHM, Look MP, et al: TSC22D1 and PSAP predict clinician outcome of tamoxifen treatment in patients with recurrent breast cancer. Breast Cancer Res Treat DOI: 10.1007/s10549-008-9934-3, 2008
26. Foekens JA, Portengen H, van Putten WL, et al: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49:5823-5828, 1989
27. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, et al: How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: A retrospective study. Clin Cancer Res 11:7311-7321, 2005
28. Martens JW, Nimmrich I, Koenig T, et al: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65:4101-4117, 2005
29. Hayward JL, Carbone PP, Heuson JC, et al: Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39:1289-1293, 1977
30. EORTC Breast Cancer Cooperative Group: Manual for clinical research and treatment in breast cancer. Almere, the Netherlands, Excerpta Medical, 2000, pp 116-117
31. Urban P, Vuaroqueaux V, Labuhn M, et al: Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol 24:4245-4253, 2006
32. Van der Flier S, Brinkman A, Look MP, et al: Bcar1/p130Cas protein and primary breast cancer: Prognosis and response to tamoxifen treatment. J Natl Cancer Inst 92:120-127, 2000
33. Dorssers LCJ, Grebenchtchikov N, Brinkman A, et al: The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res 10:6194-6202, 2004
34. Dorssers LCJ, Grebenchtchikov N, Brinkman A, et al: Application of a newly developed ELISA for BCAR1 Protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Clin Chem 50:1445-1447, 2004
35. Perez-Tenorio G, Stal O: Activation of AKT/ PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86:540-545, 2002
36. Kirkegaard T, Witton CJ, McGlynn LM, et al: AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139-146, 2005
37. Wilson GR, Cramer A, Welman A, et al: Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer 95:1410-1414, 2006
38. Wright C, Nicholson S, Angus B, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992
39. Dowsett M, Harper-Wynne C, Boeddinghaus I, et al: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61:8452-8458, 2001
40. Cobleigh MA, Tabesh B, Bitterman P, et al: Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11:8623-8631, 2005
41. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
42. Johnston SR, Leary A, Martin LA, et al: Enhancing endocrine response with novel targeted therapies: Why have the clinical trials to date failed to deliver on the preclinical promise? Cancer 112:710-717, 2007
43. Miller WR: ERBB2 status and outcome of endocrine treatment. Lancet Oncol 9:4-5, 2008
44. Kao J, Pollack JR: RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 45:761-769, 2006
45. Bai T, Luoh SW: GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation. Carcinogenesis 29:473-479, 2008
46. Brinkmeier ML, Potok MA, Cha KB, et al: TCF and Groucho-related genes influence pituitary growth and development. Mol Endocrinol 17:2152-2161, 2003
47. Hasson P, Egoz N, Winkler C, et al: EGFR signaling attenuates Groucho-dependent repression to antagonize Notch transcriptional output. Nat Genet 37:101-105, 2005
48. Cuevas IC, Slocum AL, Jun P, et al: Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 65:5070-5075, 2005
49. Felekkis KN, Narsimhan RP, Near R, et al: AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res 3:32-41, 2005
50. Schrecengost RS, Riggins RB, Thomas KS, et al: Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res 67:6174-6182, 2007
51. Nicholson S, Halcrow P, Farndon JR, et al: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i:182-185, 1989
52. Klijn JGM, Berns PMJJ, Schmitz PIM, et al: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr Rev 13:3-17, 1992
53. Van Agthoven T, Timmermans M, Foekens JA, et al: Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol 144:1238-1246, 1994
54. Bacus SS, Altomare DA, Lyass L, et al: AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21:3532-3540, 2002
55. Gizard F, Robillard R, Barbier O, et al: TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1. Mol Cell Biol 25:4335-4348, 2005
56. Gizard F, Robillard R, Gross B, et al: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol 26:7632-7644, 2006
57. Foekens JA, Portengen H, van Putten WL, et al: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002-7009, 1989
58. Nieto Y, Nawaz F, Jones RB, et al: Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 25:4405-4413, 2007
59. Massarweh S, Osborne CK, Creighton CJ, et al: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68:826-833, 2008
60. Guix M, Granja Nde M, Meszoely I, et al: Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 26:897-906, 2008
61. Manning BD, Cantley LC: AKT/PKB signaling: Navigating downstream. Cell 129:1261-1274, 2007
62. Brugge J, Hung MC, Mills GB: A new mutational AKTivation in the PI3K pathway. Cancer Cell 12:104-107, 2007
63. Maroulakou IG, Oemler W, Naber SP, et al: Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67:167-177, 2007
64. Meijer D, Van Agthoven T, Bosma PT, et al: Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res 4:379-386, 2006
65. Iorns E, Turner NC, Elliott R, et al: Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13:91-104, 2008
66. Swanton C, Marani M, Pardo O, et al: Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11:498-512, 2007
67. Whitehurst AW, Bodemann BO, Cardenas J, et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819, 2007
68. Berns K, Horlings HM, Hennessy BT, et al: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395-402, 2007